Matthias Hebben
Direttore Tecnico/Scientifico/R&S presso LOGICBIO THERAPEUTICS, INC.
Profilo
Matthias Hebben is currently the Vice President & Head-Technology Development at LogicBio Therapeutics, Inc. Prior to this, he worked as the Director-AAV Technology & CMC Development at Genethon from 2013 to 2019 and as the Director-R&D Virology at Valneva SE from 2008 to 2013.
Hebben received his undergraduate degree from the University of Strasbourg and his doctorate from the University of Nice Sophia Antipolis.
He also received an undergraduate degree from Louis Pasteur University.
Posizioni attive di Matthias Hebben
| Società | Posizione | Inizio |
|---|---|---|
| LOGICBIO THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/02/2019 |
Precedenti posizioni note di Matthias Hebben
| Società | Posizione | Fine |
|---|---|---|
Genethon
 Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Corporate Officer/Principal | 01/02/2019 |
| VALNEVA | Corporate Officer/Principal | 01/01/2013 |
Formazione di Matthias Hebben
| University of Nice Sophia Antipolis | Doctorate Degree |
| University of Strasbourg | Undergraduate Degree |
| Louis Pasteur University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| VALNEVA | Health Technology |
| Aziende private | 2 |
|---|---|
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Genethon
Genethon BiotechnologyHealth Technology Genethon is a biotherapy research and development firm, which engages in the design, development, and production of gene therapy treatments for rare diseases. It specializes in neuromuscular diseases, immune system or blood disorders, eye disorders, and liver and nervous system diseases. The company was founded in 1990 and is headquartered in Evry, France. | Health Technology |
- Borsa valori
- Insiders
- Matthias Hebben
